Three Lakes Consortium for PF (TLC4PF)

A multi-year initiative

PROGRAM TERM

Yale School of Medicine and University of Pittsburgh Department of Medicine

ORGANIZATIONS

The Three Lakes Consortium for PF (TLC4PF) aims to accelerate therapies for this devastating disease. TLC4PF comprises two strategic workgroups – PF Connectome and PF Translation. These workgroups will work together to identify potential treatments for PF using artificial intelligence and cutting-edge single cell profiling technologies and to validate efficacy of the molecules with human tissue-based models.

At least 10 institutions globally will be participating in the TLC4PF. Their contributions will establish pathways to the discovery, translation, and clinical testing of next generation therapies designed to stop and manage PF.

The PF Connectome workgroup is led by Naftali Kaminski, MD. Dr. Kaminski is Professor of Medicine and Pharmacology and Chief of Pulmonology, Critical Care and Sleep Medicine at Yale University School of Medicine. The lead investigator for the PF Translation workgroup is Melanie Königshoff, MD, PhD. She is a visiting professor of medicine at the University of Pittsburgh School of Medicine.

Breath Biopsy for Early PF Detection

Metabolic changes associated with IPF and interstitial lung abnormality (ILA) may lead to the production of unique, volatile, organic compounds (VOCs) detectable in breath.

EGCG for IPF

EGCG was discovered as an antifibrotic in pre-clinical in vivo studies and its mechanism of action blocking collagen accumulation published in 2017.

An Atlas of IPF Lung Cells

This research study was designed to identify the cellular changes that occur in the human lung cells as fibrosis develops.